IraSethWinerMDPhD

Obstetrics & Gynecology • Detroit, MI

Gynecologic Oncology

Gynecologic Oncology, Karmanos Cancer Institute Associate Professor, Wayne State University

Join to view full profile

Dr. Winer is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Winer's full profile

Already have an account?

Office
4100 John R
Detroit, MI 48201
Phone+1 313-576-9435

Fax+1 313-576-8988

Summary

Meet Dr. Ira S. Winer - Gynecologic Oncology

Ira S. Winer, M.D., Ph.D., member of the Gynecologic Oncology Multidisciplinary Team at the Barbara Ann Karmanos Cancer Institute.

Education & Training

Detroit Medical Center/Wayne State UniversityFellowship, Gynecologic Oncology, 2011 - 2015
University of MichiganResidency, Obstetrics and Gynecology, 2007 - 2011
University of Michigan Medical SchoolClass of 2007
University of MichiganPhD, The Cellular and Molecular Biology Program, 2001 - 2005
Boston UniversityBA, Biochemistry, Molecular Biology, Summa Cum Laude, 1999

Certifications & Licensure

MI State Medical License 2007 - 2027
OH State Medical License 2010 - 2011
American Board of Obstetrics and Gynecology Obstetrics & Gynecology
American Board of Obstetrics and Gynecology Gynecologic Oncology

Awards, Honors, & Recognition

CCITLA award NCI, 2019-2020
1st Prize in Fellow Research Section ACOG Research, 2012
Distinction in Research University of Michigan Medical School, 2007
Senior College Prize for Excellence in Biochemistry and Molecular Biology Boston University, 1999
Distinction in Major 1999
Golden Key National Honor Society Boston University, 1998
Dean's List 1998-1999
University Scholarship Boston University, 1994-1999
Fellow ACOG
Join now to see all

Clinical Trials

Niraparib Versus Niraparib-bevacizumab Combination in Women With Platinum-sensitive Epithelial Ovarian Cancer Start of enrollment: 2015 Feb 15
Completed
Phase 1, Phase 2
Folate Receptor in Diagnosing Ovarian Cancer Using Serum Samples From Patients With Newly Diagnosed Pelvic Mass or Previously Diagnosed Ovarian Cancer Start of enrollment: 2015 Aug 01
Completed
Phase 1
Triapine With Chemotherapy and Radiation Therapy in Treating Patients With IB2-IVA Cervical or Vaginal Cancer Start of enrollment: 2019 Sep 18
Active, not recruiting
Phase 1
Gemcitabine Hydrochloride Alone or With M6620 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Start of enrollment: 2016 Aug 25
Active, not recruiting
Phase 2
Carboplatin, Gemcitabine Hydrochloride, and Berzosertib in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Start of enrollment: 2017 May 16
Active, not recruiting
Phase 1
OTL38 for Intra-operative Imaging of Folate Receptor Positive Ovarian Cancer Start of enrollment: 2018 Jan 26
Completed
Phase 3
Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine Start of enrollment: 2018 Aug 29
Completed
Phase 1, Phase 2
ONC201 Plus Weekly Paclitaxel in Patients With Platinum Refractory or Resistant Ovarian Cancer Start of enrollment: 2020 Jan 21
Recruiting
Phase 2
IMGN853 With Carboplatin in Second-line Treatment of FRα Expressing, Platinum-sensitive Epithelial Ovarian Cancer Start of enrollment: 2022 Sep 28
Active, not recruiting
Phase 2
Roles: Contact
A Study of ZN-c3 and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer Start of enrollment: 2022 Jan 27
Recruiting
Phase 1, Phase 2
Roles: Contact
ASk Questions in GYnecologic Oncology (ASQ-GYO) Start of enrollment: 2024 Apr 04
Recruiting
Not Applicable
Roles: Sponsor-Investigator, Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

9 citations
Assessment of immune biomarkers and establishing a triple negative phenotype in gynecologic cancers.
G. Contos, Yasmine Baca, Joanne Xiu, Jennifer Brown, Robert W. Holloway
Gynecologic Oncology. 2021-11-01
633 citations
Effective expression of small interfering RNA in human cells
Cynthia P. Paul, Paul D. Good, Ira Winer, David R. Engelke
Nature Biotechnology. 2002-05-01
14 citations
Molecular profiles of endometrial cancer tumors among Black patients.
Annelise M Wilhite, Yasmine Baca, Joanne Xiu, Rajesh Paladugu, Adam C ElNaggar
Gynecologic Oncology. 2022-07-01

Journal Articles

Merkel cell carcinoma in a patient with noninvasive vulvar Paget's disease
Winer IS, Lonardo F, Johnson SC, Deppe G., Am J Obstet Gynecol, 3/30/2013
Chemotherapy of vulvar cancer: A Review
Deppe G, Mert I, Belotte J, WinerIS, Wien KlinWochenschr, 3/1/2013
Clinical and Pathologic Characteristics of Serous Carcinoma Confined to the Endometrium: A Multi-institutional Study
Seeman A, Mert I, Munkarah A, Bandyopadhyay S, Winer I, et al., Int J GynecolPathol, 3/1/2013
Correlation of tumor size with other prognostic factors in uterine serous carcinoma: A large multi-institutional study
Winer IS, Mahdi HS, Bandyopadhyay S, et al., GynecolOncol, 2/1/2013
F3-Targeted Cisplatin-Hydrogel Nanoparticles as an Effective Therapeutic that Targets Both Murine and Human Ovarian Tumor Endothelial Cells In vivo
Winer I, Wang S, Lee Y-E, Fan W, Gong Y, Buros-Ojeda D, Spahlinger G, Kopelman, Buckanovich RJ, Cancer Res., 11/1/2010
A case of progressive mucinous ovarian cancer of low malignant potential responsive to biologic therapy with Bevacizumab
Winer I, Buckanovich RJ, Gynecol Oncol, 3/1/2010
Bevacizumab for the Treatment of Non-ResectablePseudomyxomaperitonei Associated with Mucinous Ovarian Tumor of Low Malignant Potential – A Comparison of Two Cases
Winer I, Buckanovich RJ, Case Rep Oncol, 1/1/2010
Effective Expression of Small Interfering RNA in human cells
Paul C, Good P, Winer I, Engelke DR, Nature Biotechnology, 1/1/2009
Drosophila split ends homologue SHARP functions as a positive regulator of Wnt/beta-catenin/T-cell factor signaling in neoplastic transformation
ChoKR,Fearon ER, Cancer Res., 1/15/2007
Winer I, Gonik, N., Fearon, E.R, JBC, 1/1/2006
Expression of 12-Lipoxygenase as a biomarker for Melanoma Carcinogenesis
Winer I, Normolle DP, Shureiqi I, Sondak VK, Johnson T, Su L, Brenner DE., Melanoma Research, 1/1/2002
Kolligs FT, Nieman M, Winer I, Hu G, Van Mater D, Feng Y, Smith I, Wu R, Zhai Y, Cho K, Fearon ER, Cancer Cell, 1/1/2002
Join now to see all

Books/Book Chapters

Know Thy Place
Chapter: Jonathan Adams Allen
Winer IAnn Arbor: University of Michigan Press2000

Abstracts/Posters

The significance of squamous vs. adenocarcinoma subtypes in early stage cervical carcinoma
Winer I, Alvarado-Cabrero I, Seward S, Valencia-Cedillo R, Munkarah A, Ali-Fehmi R., American Association of Cancer Research Annual Meeting, 4/1/2013
A multi-institutional clinic-pathologic study of USC without myometrial invasion
Winer I, Semaan A,Mert I, Hayek K, Bandyopadhyay S, Nucci MR, Van de Vijver KK, Hussein Y, Alosh B, Oliva E, Ali-Fehmi R, International Gynecologic Cancer Society (IGCS),, 10/1/2012
Activation of the unfolded protein response (UPR) by disulfiram in ovarian cancer cells: A novel therapeutic mechanism to overcome chemoresistance
Winer et al., International Journal of Gynecological Cancer, 10/1/2012
Histone deacetylase inhibition in ovarian cancer
Winer et al., Gynecologic Oncology, 1/1/2008
Vascular targeted cisplatin nanoparticles for ovarian cancer therapy
Winer et al., Gynecologic Oncology, 1/1/2008
12-Lipoxygenase Expression in Human Pigmented Skin Neoplasia
Winer et al., Proceedings of the American Association for Cancer Research, 1/1/2001
Disufiram (Antabuse) Activates the Unfolded Protein Response to Overcome Chemoresistance in Ovarian Cancer Cells
Winer et al., MSACOG Resident/Fellow Research Day
Join now to see all

Press Mentions

How Instagram Inspired This Ovarian Cancer Survivor to Start a Nationwide Support GroupJanuary 3rd, 2023
School Celebrates Faculty Promotions, Tenure and Awards Sept. 29September 8th, 2022
Alkermes to Present Data on Nemvaleukin Alfa at the Society of Gynecologic Oncology 2022 Annual Meeting on Women’s CancerFebruary 24th, 2022
Join now to see all